Literature DB >> 8287439

Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats.

Y Kanai1, S Hori, T Tanaka, M Yasuoka, K Watanabe, N Aikawa, Y Hosoda.   

Abstract

OBJECTIVE: The aim was to clarify the role of serotonin (5-hydroxytryptamine, 5-HT) in monocrotaline induced pulmonary hypertension.
METHODS: Plasma 5-HT levels, pulmonary capillary platelet count, and vascular responsiveness to 5-HT were evaluated in the model. The effects of the selective 5-HT2 receptor antagonist, DV-7028, on the development of pulmonary hypertension were also investigated.
RESULTS: Plasma 5-HT was raised 12 h to 3 d after monocrotaline administration (60 mg.kg-1), coinciding with accumulation of platelets in the pulmonary circulation. Isolated pulmonary arteries showed hyperreactivity to 5-HT at 14 and 21 d after monocrotaline. Administration of DV-7028 (20 mg.kg-1 x d-1) attenuated the increase in pulmonary arterial pressure, right ventricular hypertrophy, and medial thickening of the pulmonary arteries.
CONCLUSIONS: The present study suggests that 5-HT released from platelets contributes to the initiation and progression of monocrotaline induced pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287439     DOI: 10.1093/cvr/27.9.1619

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Rhythmical contractions in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats.

Authors:  Akihiko Kiyoshi; Tomohisa Ishikawa; Ken-ichi Hayashi; Yoshiyuki Iwatsuki; Kunio Ishii; Koichi Nakayama
Journal:  Pflugers Arch       Date:  2003-09-27       Impact factor: 3.657

Review 3.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

4.  5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.

Authors:  M R MacLean; G Sweeney; M Baird; K M McCulloch; M Houslay; I Morecroft
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.

Authors:  Yinglin Liu; Barry L Fanburg
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

6.  Serotonin induces pulmonary artery smooth muscle cell migration.

Authors:  Regina M Day; Abena S Agyeman; Michael J Segel; Rubén D Chévere; Jill M Angelosanto; Yuichiro J Suzuki; Barry L Fanburg
Journal:  Biochem Pharmacol       Date:  2006-01-12       Impact factor: 5.858

7.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

8.  Role of the gap junctions in the contractile response to agonists in pulmonary artery from two rat models of pulmonary hypertension.

Authors:  Marie Billaud; Diana Dahan; Roger Marthan; Jean-Pierre Savineau; Christelle Guibert
Journal:  Respir Res       Date:  2011-03-17

9.  5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure.

Authors:  Wiebke Janssen; Yves Schymura; Tatyana Novoyatleva; Baktybek Kojonazarov; Mario Boehm; Astrid Wietelmann; Himal Luitel; Kirsten Murmann; Damian Richard Krompiec; Aleksandra Tretyn; Soni Savai Pullamsetti; Norbert Weissmann; Werner Seeger; Hossein Ardeschir Ghofrani; Ralph Theo Schermuly
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.